logo
Share SHARE
FONT-SIZE Plus   Neg

Merck Reports New Data From 2 Pivotal Phase III Efficacy Trials For Suvorexant

Merck (MRK) announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine company is developing for the treatment of insomnia.

In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. Merck noted that the investigational medicine met statistical significance for all primary endpoints except for one measurement at month 3 in one of the trials. These late-breaking data were presented today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

Darryle Schoepp, senior vice president and head of Neuroscience and Ophthalmology franchise, Merck Research Laboratories, stated, "Suvorexant approaches insomnia differently than other medicines because it helps patients to sleep by targeting and blocking orexins, which play a role in keeping people awake. We're excited about the Phase III results and the potential of suvorexant to become the first in a new class of medicines to help patients with insomnia."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Japanese messaging service Line Corp. announced its decision to delay the setting of a price range for its initial public offering by one day, until Tuesday, citing the chaos caused by Brexit in global markets. Line was actually planning to announce the IPO price range on Monday, June 27, and the... Fujifilm launched a new version to its tiny instant printer line up. The new upgraded version, Instax Share SP-2, can be used to print photographs from smartphones in a faster pace. China Resources Pharmaceutical Group Ltd. has filed for an initial public offering in Hong Kong stock exchange, which could turn out to be the biggest IPO of drug company this year in Asia. China Resources Pharmaceutical Group aims to raise $1 billion through the IPO. Another Chinese company, Simcere...
comments powered by Disqus
Follow RTT